Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLQ | O75417 | 3/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17602099 | 0.89 | FNTA (0.55) | ALDH1A1LMNAPOLQROCK2ROCK1 | |
| SCHEMBL2202453 | 0.88 | KDM4E (0.54) | ALDH1A1LMNAPOLQROCK2ROCK1 | |
| SCHEMBL5232476 | 0.88 | SRD5A2 (0.51) | ALDH1A1LMNAPOLQROCK2ROCK1 | |
| SCHEMBL20349603 | 0.85 | ALDH1A1 (0.52) | ALDH1A1LMNAPOLQROCK2ROCK1 | |
| SCHEMBL17602136 | 0.85 | ALOX5 (0.59) | ALDH1A1LMNAALOX5NPC1RAB9A | |
| SCHEMBL15676809 | 0.85 | SIGMAR1 (0.56) | ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL20346359 | 0.84 | POLQ (0.47) | ALDH1A1LMNAPOLQROCK2ROCK1 | |
| SCHEMBL11630604 | 0.84 | OPRK1 (0.52) | ALDH1A1LMNAPOLQROCK2ROCK1 | |
| SCHEMBL6184565 | 0.84 | EGFR (0.48) | ALDH1A1LMNAPOLQROCK2ROCK1 | |
| SCHEMBL3884249 | 0.84 | NOTUM (0.56) | ALDH1A1LMNAPOLQROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1901902-A | Thiophene and benzothiophene hydroxamic acid derivatives | ATON PHARMA INC (US) | 2007-01-24 | — | — | CN | claimed |
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007122173-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| CN-1901902-A | Thiophene and benzothiophene hydroxamic acid derivatives | ATON PHARMA INC (US) | 2007-01-24 | — | — | CN | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| US-4028323-A | WITH A SUBSTITUTED AMINOBENZENE | CIBA-GEIGY AG (CH) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | ALDH1A1 710/4885LMNA 2979/4885POLQ 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.